Pre-Existing Immunity Predicts Response to First-Line Immunotherapy in Non-Small Cell Lung Cancer Patients.
MDSCs
NSCLC
PD-1
T cells
Tregs
immunotherapy
pre-existing immunity
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
28 Jun 2024
28 Jun 2024
Historique:
received:
25
05
2024
revised:
24
06
2024
accepted:
26
06
2024
medline:
13
7
2024
pubmed:
13
7
2024
entrez:
13
7
2024
Statut:
epublish
Résumé
T-cell-mediated anti-tumoral responses may have significant clinical relevance as a biomarker for response to immunotherapy. The value of peripheral blood pre-existing tumor antigen-specific T cells (PreI
Identifiants
pubmed: 39001455
pii: cancers16132393
doi: 10.3390/cancers16132393
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RE-SEARCH-CREATE-INNOVATE
ID : Τ2ΕΔΚ-02218